Nanjing Leads Biolabs Co (HKSE:09887) Research & Development: HK$317.8 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:09887 Nanjing Leads Biolabs Co Ltd HKSE:09887
10 GF Score
Price HK$74.60
! 1 Warning Sign
View Full Analysis

What is Nanjing Leads Biolabs Co Research & Development?

Nanjing Leads Biolabs Co HKSE:09887 +8.04% 10 Research & Development is HK$317.8 Mil as of Dec. 2025. GuruFocus rates HKSE:09887 with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Nanjing Leads Biolabs Co's Research & Development for the six months ended in Dec. 2025 was HK$173.7 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 was HK$317.8 Mil.

Nanjing Leads Biolabs Co  (HKSE:09887) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Nanjing Leads Biolabs Co Research & Development Related Terms

Nanjing Leads Biolabs Co Research & Development Historical Data

* Premium members only.

The historical data trend for Nanjing Leads Biolabs Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Nanjing Leads Biolabs Co Research & Development Chart

Nanjing Leads Biolabs Co Annual Data
Trend Dec23 Dec24 Dec25
Research & Development
252.51 198.25 319.36

Nanjing Leads Biolabs Co Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
Research & Development 0.00 90.43 108.57 144.08 173.75
HKSE:09887
10GF Score
Nanjing Leads Biolabs Co Ltd HKSE:09887
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Nanjing Leads Biolabs Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$317.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$317.8 Mil mean?
Nanjing Leads Biolabs Co (HKSE:09887) has a Research & Development of HK$317.8 Mil as of Dec. 2025. Research and development expense is the total cost for research and development activities. View historical data on Nanjing Leads Biolabs Co and its competitors.
Is Nanjing Leads Biolabs Co's Research & Development too high?
Nanjing Leads Biolabs Co's current Research & Development is HK$317.8 Mil. Overall, Nanjing Leads Biolabs Co has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Nanjing Leads Biolabs Co's Research & Development compare to VRTX and REGN?
Nanjing Leads Biolabs Co's Research & Development of HK$317.8 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Nanjing Leads Biolabs Co and its competitors. Nanjing Leads Biolabs Co's current Research & Development is HK$317.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Nanjing Leads Biolabs Co stock overvalued right now?
Nanjing Leads Biolabs Co (HKSE:09887) has a current Research & Development of HK$317.8 Mil. The current Research & Development is HK$317.8 Mil. Nanjing Leads Biolabs Co's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Nanjing Leads Biolabs Co (HKSE:09887), the current Research & Development is HK$317.8 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Nanjing Leads Biolabs Co Business Description

Other Exchanges 0DX:Germany
Address Jialingjiang Street, 18E, Floor 8, Building 03, Jiangsu Province, Nanjing, CHN, 210019
Nanjing Leads Biolabs Co Ltd is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of new therapies in oncology, autoimmune, and other severe diseases. The Group uses its science-driven R&D approach and three proprietary technology platforms: X-body (4-1BB Engager), LeadsBody (CD3 T Cell Engager), and TOPiKinectics (ADC), for its multi-modal, differentiated pipeline in oncology and autoimmune diseases. It has approximately fourteen drug candidates across oncology and autoimmune diseases. Among these, one core product (LBL-024, a pivotal-stage PD-L1 and 4-1BB dual-targeting bispecific antibody) is being evaluated in several cancer indications and across various Proof-of-Concept (POC) studies. The Group generates maximum revenue from the USA.
10GF Score

Get the complete analysis for HKSE:09887

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$74.60
Price